Skip to main content

BV

Stock
Industrials
Specialty Business Services

Performance overview

BV Price
Price Chart

Forward-looking statistics

Beta
1.23
Risk
39.24%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

BrightView Holdings Inc is a provider of commercial landscaping services in the United States. The company provides commercial landscaping services, landscape maintenance, and enhancements to tree care and landscape development. It operates through two segments namely Maintenance Services, and Development Services. The Maintenance Services are self-performed through a national branch network and are route-based in nature, and the Development Services are comprised of sophisticated design, coordination, and installation of landscapes at recognizable corporate, athletic, and university complexes. The company generates a majority of its revenue from Maintenance Services.

Company info

SectorIndustrials
IndustrySpecialty Business Services
Employees13K
Market cap$1.3B

Fundamentals

Enterprise value$2.8B
Revenue$2.7B
Revenue per employee—
Profit margin1.65%
Debt to equity49.81

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)-$0.02
Dividend per share—
Revenue per share$28.66
Avg trading volume (30 day)$15M
Avg trading volume (10 day)$19M
Put-call ratio—

Macro factor sensitivity

Growth+0.1
Credit+6.0
Liquidity+0.3
Inflation-3.1
Commodities-0.4
Interest Rates-3.0

Valuation

Dividend yield0.00%
PEG Ratio18.26
Price to sales0.55
P/E Ratio18.26
Enterprise Value to Revenue1.04
Price to book1.19

Upcoming events

Next earnings dayJuly 29, 2025
Next dividend day—
Ex. dividend day—

News

Why Banco Bilbao (BBVA) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Banco Bilbao (BBVA) have what it takes?

Zacks Investment Research (July 11, 2025)
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?

AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.

Zacks Investment Research (July 11, 2025)
Why Is AbbVie Stock Trading Higher On Thursday?

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. ABBV, on Thursday, announced an exclusive licensing agreement for IGI's lead investigational asset, ISBĀ 2001, developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases.

Benzinga (July 10, 2025)
Final Trades: Abbvie, Boeing, Oracle and Joby Aviation

The Investment Committee give you their top stocks to watch for the second half.

CNBC Television (July 10, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free